SecBot SecBot
8-K ·Filed Jun 18, 2026

PHGE

BiomX Inc.
NEUTRAL
Impact 2/10
Horizonmonths Processed5mo ago SEC0001213900-26-069911
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor for future filings that provide revenue or contract wins from the defense portfolio, and watch for NYSE American compliance updates. The stock's micro-cap status and going-concern risk warrant caution; any material financial disclosure would be a significant catalyst.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$0.5199
T+0 close · Jun 18, 2026 · via day close
Latest settled
+255.84%
T+60 · $1.85
Vs SPY
+253.94%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 18 $0.5199entry
  2. T+1 · 5mo ago −13.44%α −13.13% · $0.4500
  3. T+5 · 5mo ago −24.02%α −22.36% · $0.3950
  4. T+20 · 4mo ago −60.18%α −60.72% · $0.2070
  5. T+60 · 2mo ago +255.84%α +253.94% · $1.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BiomX filed an 8-K posting an updated investor presentation detailing its completed strategic transition from clinical-stage biotech to a defense and security technology holding company. The presentation describes its portfolio (Zorronet AI C5ISR platform and DFSL LADAR detection), leadership, and growth strategy but provides no financial data, revenue, or guidance. This is a routine informational update with no material new financial information.

Key Facts

  • BiomX has completed its strategic transition from clinical-stage biotech to a defense and security technology holding company.
  • The portfolio includes Zorronet (AI-powered Autonomous Command Center platform, 100% owned) and DFSL (LADAR-based threat detection, 60% owned).
  • The presentation highlights leadership with experience from Mossad, Elbit Systems, and IDF, and an advisory board including a former Deputy Head of the Mossad.
  • The company acknowledges a going-concern qualification in its financial statements and is focused on implementing its NYSE American compliance plan.
  • No financial data, revenue, earnings, or guidance were provided in this filing.

Financial Impact

No financial figures disclosed; filing is qualitative and forward-looking.

Risk Factors

  • Going-concern qualification in financial statements indicates substantial doubt about ability to continue as a going concern.
  • Risk of delisting from NYSE American if compliance plan is not executed.
  • Customer concentration with reliance on a limited number of key relationships (Elbit Systems, Rafael).
  • Need for additional capital to fund operations and growth strategy.
  • Geopolitical risks related to Israeli operations and export control laws.

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-069911
Document: ea0295251-8k_biomx.htm0001213900-26-069911
Document: ea029525101ex99-1.htm0001213900-26-069911
Document: 0001213900-26-069911-index-headers.html0001213900-26-069911
Document: 0001213900-26-069911-index.html0001213900-26-069911
Document: 0001213900-26-069911.txt0001213900-26-069911

US Market Status

Market Closed · Opens in 4h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 18, 2026